International Society of Nephrology’s Post

Enjoy the latest edition of ISN-ACT Global Trials Focus (GTF), a monthly list identifying and summarizing recent interesting trials relevant to kidney disease. Each trial is reviewed in context and assessed for its risk of bias in key areas ➡ https://ow.ly/z4H750T1ZWX ➡️ The TOM of this month goes to the FLOW trial, showing the FLOWing Benefits of Semaglutide in People with Type 2 Diabetes and CKD published NEJM. ➡️ Spironolactone didn't show any benefit on Kidney Function in Kidney Transplant Recipients. The SPIREN trial results were published CJASN. This scientific resource is made available to the global kidney health community thanks to the continued support of ISN Members. Renew/join the ISN and help us advance kidney health - together ➡️ https://ow.ly/ByKk50T1ZWY #ThisIsISN - Advancing kidney health worldwide. Together.

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics